{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-001757","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2023-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.359751+00:00","generated_at":"2026-06-20T06:57:42.249463+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Arrowhead amends bylaws to add proxy access, update stockholder nomination rules","bullets":["Board adopted Second Amended and Restated Bylaws effective January 24, 2023.","Adds proxy access: stockholder or group of up to 20 owning 3% for 3 years may nominate up to 20% of board or two directors.","Updates procedural mechanics for stockholder nominations and business proposals.","Requires a proxy card color other than white for stockholders soliciting proxies from others.","Conforms bylaws to recent Delaware General Corporation Law amendments."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-001757","json":"https://secwatch.observer/filing/0001628280-23-001757.json","markdown":"https://secwatch.observer/filing/0001628280-23-001757.md","text":"https://secwatch.observer/filing/0001628280-23-001757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828023001757/0001628280-23-001757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828023001757/arwr-20230124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T06:57:42.249463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21dccbfdb4fde4322ceab1fd078020ebc79b9e2c","claim":"ARROWHEAD PHARMACEUTICALS, INC.: Amended and restated bylaws with updates including proxy access provisions, procedural mechanics, and conforming changes (effective 2023-01-24).","evidence_excerpt":"On January 24, 2023, the Board of Directors (the “Board”) of Arrowhead Pharmaceuticals, Inc. (the “Company”) amended and restated the Company's Amended and Restated Bylaws (the “Second Amended and Restated Bylaws”), which became effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023001757/0001628280-23-001757-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-01-24"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}